{
  "_id": "d6194d2fc7cc9dac090108ad1b4ae88c9d48889f98941ff7266aba7861c55bcb",
  "feed": "market-watch",
  "title": "Amgen reportedly in talks to buy Horizon Therapeutics",
  "text": "<p>A deal could be finalized by Monday assuming the talks with Amgen don't fall apart, the people said.</p><p>Horizon develops medicines to treat rare autoimmune and severe inflammatory diseases that are currently sold mostly in the U.S. Its biggest drug, Tepezza, is used to treat thyroid eye disease, an affliction characterized by progressive inflammation and damage to tissues around the eyes.</p><p>The company is Nasdaq-listed, but based in Ireland and has operations in Dublin, Deerfield, Ill., and a new facility in Rockville, Md.</p><p>An expanded version of this report can be found at WSJ.com</p><p>Amgen reportedly in talks to buy Horizon Therapeutics</p>",
  "published": "2022-12-12T06:36:00.000Z",
  "tags": [
    {
      "id": "US0311621009",
      "nexusId": "10036019",
      "name": "Amgen Inc.",
      "offsets": [
        {
          "start": 0,
          "end": 5
        },
        {
          "start": 583,
          "end": 588
        },
        {
          "start": 60,
          "end": 65
        }
      ]
    }
  ]
}